Stay updated on Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial page.

Latest updates to the Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe website’s revision/build label for the ClinicalTrials.gov page was updated from v3.5.2 to v3.5.3, indicating a backend or UI version change rather than a change to the displayed study content.SummaryDifference0.0%

- Check22 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check36 days agoChange DetectedAdded the Lancet Oncology publication citation for SERENA-2 and removed the associated Erratum reference.SummaryDifference0.0%

- Check51 days agoChange DetectedNaples, Italy, 80131 was added as a study location and Napoli, Italy, 80131 was replaced with the English name Naples. The page revision was updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check65 days agoChange DetectedPublication entry for SERENA-2 (Lancet Oncol. 2024) and its erratum added; the entry revision updated from v3.4.2 to v3.4.3 to reflect this change.SummaryDifference0.1%

- Check86 days agoChange Detected- Page revision updated from v3.4.1 to v3.4.2. No substantive changes to core study details were observed.SummaryDifference0.0%

Stay in the know with updates to Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial page.